United States Tumor Ablation Market 2031 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

The global Tumor Ablation Market is expected to witness significant growth during the forecast period from 2024 to 2031, with a projected compound annual growth rate (CAGR) of 13.1%. Tumor ablation procedures, which include radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, high-intensity focused ultrasound (HIFU), and laser ablation, offer minimally invasive treatment options for various cancers. Growing prevalence of cancer, technological advancements in ablation therapies, and the rising demand for less invasive cancer treatments are driving the market's promising outlook.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/tumor-ablation-market?sb

Key Development:

United States: Recent Tumor Ablation Developments

✅ In November 2025, Williams Cancer Institute reported that combining pulsed‐electric‐field (PEF) ablation with intratumoral immunotherapy led to substantial regression of an advanced head‐and‐neck tumor with no treatment‐related toxicity, showing promise for hard‐to‐treat cancers.

✅ In November 2025, Galvanize Therapeutics announced six‐month results from its AFFINITY trial indicating that its PEF ablation system ("Aliya®") achieved local control of lung tumors in metastatic cancer patients suggesting potential for lung‐tumor ablation beyond conventional therapies.

✅ In November 2025, Focal One HIFU system received 510(k) clearance from U.S. Food and Drug Administration (FDA) after enhancements to imaging and workflow supporting the use of robotic high‐intensity focused ultrasound (HIFU) for focal prostate cancer treatment.

✅ In November 2025, researchers described a prototype 3‐mm MR‐compatible dual‐mode ultrasound catheter for image‐guided HIFU ablation, with improved directional ablation capability a promising step toward more precise minimally invasive thermal ablation.

✅ In November 2025, a novel dual‐mode ultrasound catheter for image‐guided high-intensity focused ultrasound (HIFU) ablation was described in preclinical work; the MR‐compatible 3‐mm catheter offers highly directional, conformal ablation a promising advance for minimally invasive thermal ablation procedures.

✅ In October 2025, CAPS Medical received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its PlasmaSure System a non‐thermal plasma‐based ablation system targeting non‐muscle invasive bladder cancer. Early studies reported durable complete responses with minimal surrounding tissue damage and good patient tolerance.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=tumor-ablation-market?sb

Japan / Asia Region: Recent Tumor Ablation Developments

✅ In October 2025, a study showed that percutaneous Microwave Ablation (MWA) remains effective for colorectal liver metastases even when some lesions disappear during pre‐ablation chemotherapy supporting MWA's utility in complex liver‐metastasis cases.

✅ In October 2025, a global review highlighted advances in both thermal (radiofrequency, microwave, cryo) and non‐thermal (ethanol ablation, irreversible electroporation) modalities for liver cancer, reinforcing the growing role of ablation therapies in Asia's hepatocellular carcinoma treatment landscape.

✅ In 2025, clinicians in Japan are increasingly exploring HIFU therapy for pancreatic cancer SONIRE Therapeutics is conducting a randomized clinical trial assessing its next‐generation HIFU system for inoperable pancreatic tumors, marking a push toward non‐surgical ablation for hard‐to‐treat cancers.

✅ In 2025, the latest guidelines from the Asian Conference on Tumor Ablation reaffirmed image‐guided percutaneous liver tumor ablation (RFA/MWA/cryoablation/IRE) as the best option for early‐stage hepatocellular carcinoma (HCC) when surgery isn't feasible, reflecting consensus and standardization in Asian oncology practice.

Market Overview

Tumor ablation techniques destroy cancerous tissue by heating or freezing targeted areas, providing an effective alternative to surgical resection. Microwave ablation currently dominates the market due to its precision, rapid action, and safety profile. Increasing availability of advanced tumor ablation devices in hospitals and clinics is propelling adoption. The market benefits from expanding geriatric populations, rising cancer incidence, and improved healthcare infrastructure globally.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/tumor-ablation-market?sb

Market Drivers

Increasing global cancer prevalence fueling demand for effective, minimally invasive treatment options. Technological innovations such as Aliya Pulsed Electric Field (PEF) technology offering new, immune-boosting ablation methods. Growing preference among patients and clinicians for less painful, outpatient cancer treatments with faster recovery. Favorable reimbursement policies enhancing patient access to ablation therapies. Ongoing research and development efforts improving procedure efficacy and safety.

Market Restraints

High costs associated with advanced ablation technologies and procedures may limit accessibility, especially in low-income regions. Limited availability of essential supplies such as argon gas for cryoablation in some geographies. Potential complications and patient-specific considerations requiring careful procedure planning.

Market Segmentation

By Technology: The market segments include microwave ablation (MWA), radiofrequency ablation (RFA), cryoablation, high-intensity focused ultrasound (HIFU), and laser ablation. Microwave ablation holds the dominant market share owing to its speed and efficacy.

By Application: Focuses on cancers of the liver, lung, breast, kidney, and others.

By Treatment Mode: Differentiates between percutaneous, laparoscopic, and open surgical ablation.

By Region: Covers North America, Europe, Asia-Pacific, South America, and Middle East & Africa.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Geographical Insights

North America dominates the tumor ablation market with about one-third of the total share, driven by cutting-edge technology adoption, supportive regulatory approvals, and increasing cancer cases. The recent FDA approval of devices like the Epione system for minimally invasive liver cancer treatment exemplifies regional innovation. Asia-Pacific is the fastest-growing region owing to rising cancer incidence, expanding healthcare infrastructure, and growing awareness.

Competitive Landscape

Key players leading the global tumor ablation market include Medtronic PLC, AngioDynamics Inc., Boston Scientific Corporation, Healthtronics, BVM Medical Limited, COMSOL, Galil Medical, INTIO Inc., Misonix Inc., NeuWave Medical, and SonaCare Medical. These companies focus on product innovation, strategic partnerships, and geographic expansions to strengthen market position.

Russia-Ukraine Conflict Analysis

The ongoing Russia-Ukraine conflict impacts the tumor ablation market through disruptions in supply chains and potential limitations in healthcare facility operations, leading to challenges in accessing timely cancer treatments. However, the impact remains moderate during the forecast period.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Why Purchase the Report?

Visualize comprehensive tumor ablation market segmentation by technology, application, treatment mode, and region.
Identify commercial opportunities and emerging trends through in-depth qualitative and quantitative research.
Access an extensive data set including 61 tables, 60 figures, and detailed company profiles.
Gain actionable insights from regulatory, pricing, supply chain, and competitive analyses.
Benefit from strategic guidance tailored for manufacturers, investors, research professionals, and emerging companies.

DataM Intelligence presents this in-depth tumor ablation market report to empower decision-makers with essential insights for strategic planning and growth in the dynamic oncology treatment landscape.

For more details, visit www.datamintelligence.com.

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.